Clinical trial
Lucentis for Central Retinal Vein Occlusion (CRVO)
NCT00406796 · California Retina Consultants, Other · Completed
Key facts
| NCT number | NCT00406796 |
|---|---|
| Title | Lucentis for Central Retinal Vein Occlusion (CRVO) |
| Official title | FVF3565s Intravitreal Ranibizumab (rhuFab V2) in the Treatment of Macular Edema Associated With Perfused Central (CRVO) Retinal Venous Occlusive Disease |
| Lead sponsor | California Retina Consultants, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Central Retinal Vein Occlusion |
| Intervention type | Drug |
| Interventions | Ranibizumab |
| Enrollment | 20 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Oct 1, 2010 |
| First posted | Dec 4, 2006 |
| Last update posted | Dec 12, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: